NCT00515138TerminatedEarly Phase 1
A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant
University of California, San Francisco2 sites in 1 country7 target enrollmentStarted: May 1, 2007Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Early Phase 1
- Status
- Terminated
- Enrollment
- 7
- Locations
- 2
- Primary Endpoint
- -Determine the maximum tolerated dose of bortezomib in combination with rituximab, ifosfamide, carboplatin, and etoposide for patients with relapsed or primary refractory aggressive B-cell NHL
Study Overview
Brief Summary
This study seeks to determine the maximum tolerated dose of bortezomib in combination with rituximab, ifosfamide, carboplatin, and etoposide for patients with relapsed or primary refractory aggressive B-Cell Non-Hodgkin's lymphoma (diffuse large B-cell, mantle cell, follicular grade III, transformed lymphoma). Subjects will be enrolled in cohorts of 3 at each bortezomib dose level, starting at 1 mg/m(2), and escalating to 1.3, 1.5, and 1.7 mg/m(2). Bortezomib will be given on days 1 (prior to rituximab) and 4, rituximab 375 mg/m(2)/day on days 2, 3, and 4 of a 21-day cycle. They will also receive filgrastim on days 6-13 or pegfilgrastim on day 6.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Aggressive B-Cell Lymphoma, CD-20 positive, in first relapse or refractory to first-line chemotherapy
- •Diffuse large B-cell Lymphoma, Mantle cell lymphoma, Follicular lymphoma (Grade III), Transformed Follicular Lymphoma
- •Rituximab is allowed
- •Prior radiation is allowed
- •18-70 years of age
- •ECOG performance status of 0-2
- •HIV seronegative
- •Measurable disease on CT scan by international working group response criteria
- •No CNS involvement
- •Subject is considered to be a candidate for autologous stem cell transplant in the opinion of the treating physician
- •Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control
- •Male subject agrees to use an acceptable method of contraception for the duration of the study
Exclusion Criteria
- •Platelet count of <75 x 10(9)/L
- •Absolute neutrophil count of <1.0 x 10(9)/L
- •Calculated or measured creatinine clearance of <60 mL/minute within 14 days before enrollment
- •Myocardial infarction within 6 months prior to enrollment or has New York Hospital Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.
- •Subject has hypersensitivity to bortezomib, boron or mannitol.
- •Female subject is pregnant or breast-feeding.
- •Subject has been treated with more than one prior chemotherapy regimen.
- •Subject has received other investigational drugs with 14 days before enrollment.
- •Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
Outcomes
Primary Outcomes
-Determine the maximum tolerated dose of bortezomib in combination with rituximab, ifosfamide, carboplatin, and etoposide for patients with relapsed or primary refractory aggressive B-cell NHL
Time Frame: 3 years
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Active, not recruiting
Not Applicable
Pilot study of bortezomib under rituximab standard therapy in patients with relapsed or refractory follicular lymphoma and at least 2 prior therapiesPatients with histologically proven CD-20-positive follicular lymphoma grade I/II (WHO), stage III/IV (ANN ARBOR) relapsed or refractory to last treatment after at least 2 cytostatic therapies who are to be treated with rituximab therapy.MedDRA version: 9.1Level: LLTClassification code 10016904Term: Follicle centre lymphoma, follicular grade I, II, III NOSEUCTR2005-003949-14-DEORTHO BIOTECH, Geschäftsbereich der JANSSEN-CILAG GmbH30
Completed
Phase 1
A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant PatientsHematopoetic Stem Cell TransplantNCT01926899Indiana University15
Terminated
Phase 2
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular LymphomaLymphoma, FollicularNCT01902862Janssen-Cilag G.m.b.H7
Completed
Phase 1
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell LymphomaMantle Cell LymphomaNCT00477412M.D. Anderson Cancer Center107
Terminated
Phase 2
Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) LymphomaPrimary Central Nervous System LymphomaNCT02113007SCRI Development Innovations, LLC2